{"page_content": "ESG Report 2023\nThrough our pioneering leadership  in PK activation, we are  \nmaking a difference for people with rare disease s\n1st Disease-modifying \nTherapy for PK \nDeficiency1st Global \nPK Deficiency \nRegistry1st Pediatric Study \nof a PK Activator1st Company \nto Pursue MDS \nwith a PK Activator1st Clinical Trial \nEvaluating \nDisease-modifying\nTreatment in Alpha-\nThalassemia\n+ A Lot of FirstsPivotal  \nClinical Programs PublicationsDiseases with  \nPOC Achieved\nPK DEFICIENCY \nTHALASSEMIA\nSICKLE CELL DISEASE\n6", "metadata": {"source": "NASDAQ_AGIO_2022.pdf", "page": 5, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}